We carry out pre-clinical and clinical research to develop new products and ensure that they are safe to use.
We focus our R&D efforts on disease areas where there is still significant need for better treatment options and where we believe our skills will help us achieve our vision of providing new health solutions advancing human life.
Currently, we run over 15 ongoing interventional clinical studies. 2019 was also a significant year in terms of our pre-clinical developments. We presented an update on the clinical development plan and pre-clinical data with SubQ-8, a novel subcutaneous recombinant factor VIII (FVIII) in development, at the 27th International Society on Thrombosis and Haemostasis (ISTH) Congress in Melbourne, Australia, ISTH 2019.
Preclinical R&D is the research and development work we undertake before we create a new medicine.
Our preclinical plasma research and development work is carried out at our state-of-the-art site in Vienna, Austria. There, we develop novel plasma-derived products. We also create new technologies to improve our work and new devices to help patients at home or in hospital. We maintain a strong focus on key regulatory, production, life-cycle management and marketing matters.
Recombinant R&D involves the development of therapeutic recombinant proteins that resemble the respective proteins in human tissue or blood. These gives the best results in patients. This research work is carried out at our Heidelberg site, in Germany.
The molecular biochemistry group in Berlin, Germany, develops technologies to examine the structure and function of plasma-derived and recombinant proteins. It has developed new ways to decode the relationships between different plasma proteins and their influence on the immune system.
All our medicines must help improve the lives of patients and,as part of that, they must be safe to use. It is the global virus and prion validation group that does much of the work to ensure this. The group tests and verifies the pathogen inactivation or removal methods used in all Octapharma production processes. The group is located at our facilities in Frankfurt, Germany.
The pharmacology and toxicology department in Vienna, Austria, assesses the safety of all new medicines before they are put forward for clinical trials and regulatory approval. It is this department’s responsibility to ensure that the formulation and performance of our medicines are not affected by contact with anything they are stored or distributed in. The department also works with all other departments to manage and enhance product life-cycle management.
Clinical R&D is the research and development work we undertake once a medicine has been developed and has shown the potential to go into production.
Our clinical research departments are responsible for all our product trials and for the life-cycle management support of all our marketed medicines.
Our clinical R&D sites are in Vienna, Austria; Lachen, Switzerland; and Hoboken, New Jersey, USA.